Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-0151 in Adult Participants With Rheumatoid Arthritis
NCT06902519Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of GS-0151 in rheumatoid arthritis (RA) (6 cohorts), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events up to 31 weeks, Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities up to 31 weeks and 4 more. Started May 2025; status: active, not recruiting.
02
Drugs
GS-0151
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06902519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902519.